Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06753916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

Study acronym: ExCrossV
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 2 of 4 entries
    • Study description revised
    • Site details revised at 1 of 12 sites
  2. Site details revised at 5 of 12 sitesv5
  3. Study sites: 10 to 12v4
  4. Site details revised at 4 of 10 sitesv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2025 to Apr 1, 2025
    • Study sites revised (10)
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Trial Details
NCT Number NCT06753916
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Corneal Transplant Failure
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov